Literature DB >> 28301338

Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer: Overtreatment Is the Main Issue.

Alper Karalok1, Taner Turan, Derman Basaran, Osman Turkmen, Gunsu Comert Kimyon, Gokhan Tulunay, Tolga Tasci.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the effectiveness of histological grade, depth of myometrial invasion, and tumor size to identify lymph node metastasis (LNM) in patients with endometrioid endometrial cancer (EC).
METHODS: A retrospective computerized database search was performed to identify patients who underwent comprehensive surgical staging for EC between January 1993 and December 2015. The inclusion criterion was endometrioid type EC limited to the uterine corpus. The associations between LNM and surgicopathological factors were evaluated by univariate and multivariate analyses.
RESULTS: In total, 368 patients were included. Fifty-five patients (14.9%) had LNM. Median tumor sizes were 4.5 cm (range, 0.7-13 cm) and 3.5 cm (range, 0.4-33.5 cm) in patients with and without LNM, respectively (P = 0.005). No LMN was detected in patients without myometrial invasion, whereas nodal spread was observed in 7.7% of patients with superficial myometrial invasion and in 22.6% of patients with deep myometrial invasion (P < 0.0001). Lymph node metastasis tended to be more frequent in patients with grade 3 disease compared with those with grade 1 or 2 disease (P = 0.131).
CONCLUSIONS: The risk of lymph node involvement was 30%, even in patients with the highest-risk uterine factors, that is, those who had tumors of greater than 2 cm, deep myometrial invasion, and grade 3 disease, indicating that 70% of these patients underwent unnecessary lymphatic dissection. A precise balance must be achieved between the desire to prevent unnecessary lymphadenectomy and the ability to diagnose LNM.

Entities:  

Mesh:

Year:  2017        PMID: 28301338     DOI: 10.1097/IGC.0000000000000937

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients.

Authors:  Xiaoying Jin; Chunjuan Shen; Xiaodi Yang; Yayuan Yu; Jianzhang Wang; Xuan Che
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

2.  UPDATE ON SENTINEL LYMPH NODE MAPPING IN ENDOMETRIAL CANCER PATIENTS WITH A HIGH RISK FOR NODAL METASTASIS.

Authors:  Derman Basaran; Mario M Leitao
Journal:  Indian J Gynecol Oncol       Date:  2020-04-13

3.  Predicting Factors for Pelvic Lymph Node Metastasis in Patients with Apparently Early-Stage Endometrial Cancer.

Authors:  Pariyed Gumtorntip; Yenrudee Poomtavorn; Chamnan Tanprasertkul
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

4.  Systematic lymphadenectomy for intermediate risk endometrial carcinoma treatment does not improve the oncological outcome.

Authors:  Elaine C Candido; Osmar F Rangel Neto; Maria Carolina S Toledo; José Carlos C Torres; Aurea A A Cairo; Joana F Braganca; Julio C Teixeira
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-04-18

5.  Systemic Immune-Inflammatory Index as a Predictor of Lymph Node Metastasis in Endometrial Cancer.

Authors:  HuiFang Lei; ShuXia Xu; XiaoDan Mao; XiaoYing Chen; YaoJia Chen; XiaoQi Sun; PengMing Sun
Journal:  J Inflamm Res       Date:  2021-12-21

6.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.

Authors:  Tao Zhang; Qin Liu; Yingfan Zhu; Songfa Zhang; Qiaohua Peng; Amanda Louise Strickland; Wenxin Zheng; Feng Zhou
Journal:  Cancer Manag Res       Date:  2021-12-14       Impact factor: 3.989

7.  Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus.

Authors:  Vakkas Korkmaz; Mehmet Mutlu Meydanli; Ibrahim Yalçın; Mustafa Erkan Sarı; Hanifi Sahin; Eda Kocaman; Ali Haberal; Polat Dursun; Tayfun Güngör; Ali Ayhan
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.